About: Chloroquine and hydroxychloroquine ototoxicity; potential implications for SARS-CoV-2 treatment. A brief review of the literature

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Chloroquine and hydroxychloroquine ototoxicity; potential implications for SARS-CoV-2 treatment. A brief review of the literature Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Chloroquine and hydroxychloroquine ototoxicity; potential implications for SARS-CoV-2 treatment. A brief review of the literature
Creator	Claudia, Cavaliere, Matteo Claudia, Cassandro De Bonis, Egidio De Luca, Pietro Ettore, Cassandro Federico, Maria Gioacchini, Federico Gioacchini, Massimo Ralli, Cassandro Ralli, Massimo Scarpa, Alfonso Viola, Pasquale
source	Elsevier; PMC
abstract	INTRODUCTION: Current clinical evidences do not support any specific treatment against SARS-CoV-2. Chloroquine (CQ) and hydroxychloroquine (HCQ) are typically used in the treatment of rheumatoid arthritis, systemic lupus erythematosus and malaria; they have been considered for off-label and compassionate use in several countries against moderate to severe cases of COVID-19 and there's actually a massive demand of these two drugs. The aim of this paper is to briefly review the published literature, summarizing evidences about audiological implications after CQ and HCQ treatment. METHODS: We conducted a review of the literature on Medline and Pubmed platforms from 27th May 2020 to 30 May 2020. We combined MeSH terms of “chloroquine”, “hydroxychloroquine”, “ototoxicity”, “hearing loss”, “tinnitus”, “deafness” and “hearing”. Publications with relevant data were included. Selected data (authors, country and year; sample size; study design; audiological side effects) were extracted and summarized in a table. RESULTS: Of 45 initial studies, 14 met inclusion criteria. The authors found xix cases of HCQ ototoxicity; Tinnitus was reported in 2 cases, and it was found to be reversible or irreversible. Sensorineural hearing loss after HCQ use was reported in 7 patients; it was found to be irreversible or partially reversible after discontinuation of HCQ in 6 cases. Eight papers reporting CQ ototoxicity were; tinnitus was not reported by any authors. Sensorineural hearing loss after taking CQ was reported in 6 patients; it was found to be irreversible after discontinuation of CQ in 5 patients. One patient showed abnormal gait after a single intramuscular injection of CQ. Thirteen patients' Auditory Brainstem Response (ABR) were found to be abnormal, but they resolved after CQ discontinuation. CONCLUSIONS: CQ and HCQ related ototoxicity is widely reported in the literature although the pathophysiological mechanism is not well known. Current data are not sufficient enough to support the use of CQ and HCQ as therapy for COVID-19, but considering the growing demand for these two drugs and the number of people around the world who have taken and will take CQ and HCQ, it must necessarily consider the clinical and social impact of long term audiological side effects.
has issue date	2020-07-08(xsd:dateTime)
bibo:doi	10.1016/j.amjoto.2020.102640
has license	no-cc
sha1sum (hex)	3f5359a7347c4c5d2990be2a98a6f5c9e4bace92
schema:url	https://doi.org/10.1016/j.amjoto.2020.102640
resource representing a document's title	Chloroquine and hydroxychloroquine ototoxicity; potential implications for SARS-CoV-2 treatment. A brief review of the literature
has PubMed Central identifier	PMC7342085
schema:publication	Am J Otolaryngol
resource representing a document's body	covid:3f5359a7347c4c5d2990be2a98a6f5c9e4bace92#body_text
is schema:about of	named entity 'literature' named entity 'SARS-CoV-2' named entity 'Literature' named entity 'ototoxicity' named entity 'FUNDING SOURCE' named entity 'Ototoxicity' named entity 'Chloroquine' named entity 'COVID' named entity 'HCQ' named entity 'systemic lupus erythematosus' named entity 'HCQ' named entity 'labyrinthectomy' named entity 'hearing loss' named entity 'off-label' named entity 'hearing loss' named entity 'malaria' named entity 'muscle weakness' named entity 'ototoxicity' named entity 'review article' named entity 'long term' named entity 'case reports' named entity 'guinea pigs' named entity 'HCQ' named entity 'hydroxychloroquine' named entity 'COVID' named entity 'SARS-CoV-2' named entity 'round window' named entity 'HCQ' named entity 'ototoxicity' named entity 'CoronaVirus' named entity 'ototoxicity' named entity 'HCQ' named entity 'hair cells' named entity 'hearing loss' named entity 'ABR' named entity 'HCQ' named entity 'systemic lupus' named entity 'liver' named entity 'audiological' named entity 'hydroxychloroquine' named entity 'systemic lupus erythematosus' named entity 'ototoxicity' named entity 'COVID' named entity 'autoimmunity' named entity 'pregnancy' named entity 'case reports' named entity 'HCQ' named entity 'Chloroquine' named entity 'audiological' named entity 'autoimmune diseases' named entity 'pregnancy' named entity 'rheumatoid arthritis' named entity 'long time' named entity 'pregnant women' named entity 'trimester of pregnancy' named entity 'HCQ' named entity 'long-term' named entity 'Rheumatoid Arthritis' named entity 'malaria treatment' named entity 'healthcare systems' named entity 'SARS-CoV-2' named entity 'antioxidant' named entity 'hypoglycaemia' named entity 'Chalumeau' named entity 'HCQ' named entity 'HCQ' named entity 'audiological' named entity 'HCQ' named entity 'case reports' named entity 'kidney problems' named entity 'HCQ'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software